Incidence of different types of cancer in the follow-up period after primary diagnosis and treatment of melanoma. Single-centre 4-year follow-up on a population of 709 patients.
basal cell carcinoma
follow-up
melanoma
squamous cell carcinoma
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
21
03
2023
accepted:
23
04
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Follow-up plays a key role in melanoma management, especially in the first years after diagnosis. During this period it is crucial to assess possible recurrence, progression of the disease or treatment complications. An important aspect is also the possibility of formation of new primary foci or other skin cancers. To assess the coincidence of skin lesions and cancers among the melanoma patients. Patients treated in the Comprehensive Cancer Centre between 2019 and 2022 were retrospectively analysed for occurrence of skin lesions diagnosed during the follow-up, and confirmed by biopsy. The lesions considered included skin cancers, dysplastic nevus and actinic keratosis. In 100 (14%) out of 709 enrolled patients, 184 lesions were diagnosed. In 7 patients it was melanoma, in 49 BCC, and in 16 SCC. Dysplastic nevus and actinic keratosis were excised in 28 and 14 patients, respectively. More than one site of the skin lesion was observed in 39 patients, and more than one type of the lesion in 13 patients. Patients with lesions were on average 8.6 years older ( Among melanoma patients, particular attention must be paid to, apart from early detection of melanoma recurrence and progression, the occurrence of new primary foci or independent skin cancers.
Identifiants
pubmed: 37545825
doi: 10.5114/ada.2023.127545
pii: 50700
pmc: PMC10399667
doi:
Types de publication
Journal Article
Langues
eng
Pagination
416-420Informations de copyright
Copyright: © 2023 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Clin Aesthet Dermatol. 2013 Sep;6(9):18-26
pubmed: 24062870
Postepy Dermatol Alergol. 2020 Oct;37(5):660-670
pubmed: 33240003
Sci Rep. 2017 Feb 15;7:42601
pubmed: 28198461
Adv Exp Med Biol. 2008;624:89-103
pubmed: 18348450
JAMA Dermatol. 2015 Oct;151(10):1103-9
pubmed: 26200476
Ann Surg Oncol. 2008 Aug;15(8):2206-14
pubmed: 18512102
Br J Dermatol. 2015 Jan;172(1):33-47
pubmed: 25204572
Arch Dermatol. 2010 Mar;146(3):265-72
pubmed: 20231496
Am J Clin Oncol. 2018 Oct;41(10):1024-1027
pubmed: 29028642
J Am Acad Dermatol. 2012 Jan;66(1):37-45
pubmed: 21700361
Cancer. 2010 Dec 15;116(24):5716-24
pubmed: 21218461
Cancer. 2017 Dec 1;123(23):4728-4736
pubmed: 28817180
J Am Acad Dermatol. 2020 Oct;83(4):1035-1043
pubmed: 32442695
Lancet Oncol. 2017 Jan;18(1):e19-e29
pubmed: 28049574
Nat Rev Clin Oncol. 2014 Jan;11(1):38-48
pubmed: 24247164
Clin Rheumatol. 2013 Feb;32(2):277-80
pubmed: 23138884
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):528-32
pubmed: 23549396
Cochrane Database Syst Rev. 2019 Nov 21;2019(11):
pubmed: 31750936
Postepy Dermatol Alergol. 2022 Dec;39(6):1141-1150
pubmed: 36685997